Plain-English Summary
SELECT is the major outcomes trial showing that semaglutide 2.4 mg reduced serious cardiovascular events in people with overweight or obesity who already had cardiovascular disease and did not have diabetes.
VV Study Evidence Matrix v1.0
VV Evidence Utility Score
A bounded score for how useful this study is in public explanation, based on evidence tier, design, applicability, endpoint relevance, limitations, safety signals, and publication/source strength.
83/100
Useful Public Evidence
- Evidence tier
- 92/100, weight 18%
- Design strength
- 100/100, weight 18%
- Applicability
- 75/100, weight 16%
- Endpoint relevance
- 88/100, weight 16%
- Limitations transparency
- 70/100, weight 12%
- Safety signal usefulness
- 45/100, weight 10%
- Publication/source strength
- 90/100, weight 10%
Useful for context, but limited by safety signal usefulness, limitations transparency, applicability.
How the study framework works ->Key Findings
- Semaglutide reduced the risk of the composite major adverse cardiovascular event endpoint versus placebo in adults with overweight or obesity and established cardiovascular disease without diabetes.
- The effect moved semaglutide beyond cosmetic weight-loss framing and into cardiometabolic outcomes in a high-risk population.
- The outcome population was specific: established cardiovascular disease, overweight or obesity, and no diabetes.
Limitations
- The results should not be generalized to lower-risk consumers without established cardiovascular disease.
- SELECT does not prove that every use of semaglutide for weight loss produces cardiovascular-event reduction.
- The trial evaluates semaglutide 2.4 mg with standard care, not compounded versions or unsupervised use.
Why It Matters
This is the strongest counter to the claim that GLP-1 drugs are only vanity weight-loss drugs, while still requiring careful population-specific framing.
Viral Vitalism Verdict
High-impact outcomes evidence, but only for the studied risk group. Use it to upgrade the GLP-1 narrative, not to overgeneralize cardioprotection to everyone.
Sources
- Semaglutide and cardiovascular outcomes in obesity without diabetes - New England Journal of Medicine
- SELECT trial: semaglutide and cardiovascular outcomes - PubMed
Signal cards
Used in signals
Signal coverage connected to this study through explicit study links, canonical source refs, or evidence visualizations.
GLP-1s Are Not Just a Weight Loss Story
GLP-1 medications are being studied for effects that may extend beyond weight loss, including cardiometabolic outcomes and behavior-related pathways.
VV Signal Score
76
Promising signal
- Sources
- 31
- Studies
- 11
- Claims
- 16
Claim ledger
Relevant claims
Claim ledger records connected through this study's ID, topic tags, or source IDs.
semaglutide: Semaglutide reduced major adverse cardiovascular events in SELECT participants
Semaglutide reduced major adverse cardiovascular events in SELECT participants with overweight or obesity and established cardiovascular disease without diabetes.
glp 1: GLP-1-based therapies have demonstrated outcome benefits beyond weight loss
GLP-1-based therapies have demonstrated outcome benefits beyond weight loss in specific high-risk cardiometabolic populations.
semaglutide: Semaglutide reduced body weight in adults with obesity or
Semaglutide reduced body weight in adults with obesity or overweight in randomized clinical-trial populations.
glp 1: Semaglutide and tirzepatide should not be collapsed into one
Semaglutide and tirzepatide should not be collapsed into one generic claim because their mechanisms, labels, trial programs, and outcome evidence differ.
glp 1: Semaglutide and tirzepatide produce clinically meaningful average weight loss
Semaglutide and tirzepatide produce clinically meaningful average weight loss in studied adults with obesity or overweight, with results and tolerability varying by drug, dose, and patient context.
glp 1: FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled
FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled products are different regulatory and quality-risk categories.